Source: Lieyun Network
Recently, Oricell Therapeutics Holdings Limited, a leading global innovator in tumor immunotherapy, completed a Pre-IPO financing round of US$110 million. This round was co-led by Vivo Capital, Beijing Medical and Health Industry Investment Fund, Qiming Venture Partners, and a globally leading healthcare fund. Notable institutions such as an international sovereign fund, Yizhuang Guotou, Luxin Venture Capital, NGS (Australian pension fund), Richelieu Investment, and Ruifeng Capital also participated as follow-on investors.
It is reported that the proceeds from this round of financing will be mainly used to accelerate the international strategic layout of Qrigincell Therapeutics, promote the global multi-center clinical development of its core pipeline, further consolidate its technical barriers in the cell therapy field, and expedite the value release of its industrialization pipeline, in order to make full preparations for the upcoming capital market milestone.
As a leading company in the field of cell therapy drugs, Qrigincell Therapeutics has always been committed to developing CAR-T cell therapies with global clinical value and has already achieved confirmatory Proof of Concept (POC) clinical data across multiple pipelines. Relying on the company's self-innovated Ori®Ab antibody screening and engineering platform, Ori®Armoring structure enhancement platform, and OnGo (Fast) CMC rapid process expertise, Qrigincell Therapeutics has successfully built a differentiated product pipeline, securing a strong position in the global CAR-T technology competition.
The core product of Qrigincell Therapeutics includes Ori-C101, an autologous CAR-T drug targeting GPC3 for the treatment of advanced hepatocellular carcinoma (HCC). This product has completed investigator-initiated clinical trials (IIT) and Phase I registrational clinical trials, and is about to launch pivotal clinical trials. The currently available clinical data demonstrate excellent efficacy and safety profiles, with related findings being presented multiple times at top international academic conferences such as ASCO (American Society of Clinical Oncology Annual Meeting). With its positive clinical progress so far, Ori-C101 is expected to become the world’s first approved CAR-T drug for hepatocellular carcinoma.
In addition to its core pipeline, Qrigincell Therapeutics' full-platform technology system is continuously incubating multiple next-generation multi-target, multi-mechanism CAR-T products, including secretory, rapid production, and several in vivo CAR-T projects.
Dr. Yang Huanfeng, Chairman and CEO of Qrigincell Therapeutics, stated: "We will continue to focus on the global clinical advancement of our core pipelines, deepen the research and development of revolutionary technologies such as in vivo CAR-T and solid tumor CAR-T, and fully leverage the company's multiple advantages in technological accumulation, policy environment, and market demand. We aim to accelerate the development speed of clinical-stage products, reduce costs, and increase accessibility. Our goal is to provide more groundbreaking cell therapy solutions, bringing new hope of a cure to cancer patients worldwide, and steadily advancing towards becoming a leading global immunotherapy enterprise."